<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005303</url>
  </required_header>
  <id_info>
    <org_study_id>RGHT000395</org_study_id>
    <nct_id>NCT01005303</nct_id>
  </id_info>
  <brief_title>Micronutrient Supplementation in Patients With Heart Failure</brief_title>
  <acronym>MINT-HF</acronym>
  <official_title>A Trial of Micronutrient Supplementation in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belfast Health and Social Care Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence to suggest that patients with heart failure may have a reduced dietary
      intake of vitamins and essential minerals (micronutrients) and that this may worsen the
      function of the heart. This study is designed to investigate if supplementation with
      micronutrients (including highâˆ’dose vitamin D) will improve the function of the heart in
      patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Volumes</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Inflammation</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Oxidative Stress</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Cardiac Function</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Functioning</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronutrient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 Tablet Daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forceval plus 50 micrograms Vitamin D3</intervention_name>
    <description>Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily</description>
    <arm_group_label>Micronutrient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New York Heart Association Class II and III

          -  Already on or tried on best known medical treatment (ACE inhibitor and beta-blocker)

          -  Stable for a period of at least 6 weeks

          -  Left ventricular ejection fraction less than or equal to 45%

        Exclusion Criteria:

          -  History of significant alcohol ingestion (more than 40 units per week)

          -  Severe renal dysfunction (GFR less than 30ml/min)

          -  Severe hepatic dysfunction (known liver disease or transaminases greater than 3 times
             the upper limit of normal)

          -  Atrial fibrillation (in the absence of a pacemaker)

          -  Frequent ventricular ectopics

          -  On waiting list for cardiac transplantation

          -  Uncontrolled diabetes mellitus

          -  Inability to give informed consent

          -  Estimated life span less than 12 months

          -  Already taking a multivitamin/mineral supplement

          -  Already taking a vitamin-D containing fish oil

          -  Woman of child-bearing potential

          -  History of renal stones, hypercalcaemia, sarcoidosis, haemochromatosis or lactose
             intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal McKeown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belfast Health and Social Care Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Harbinson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Belfast Health and Socail Care Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle McKinley, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Queen's Univeristy of Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belfast Health and Social Care Trust</investigator_affiliation>
    <investigator_full_name>Pascal McKeown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Physical Functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Micronutrients</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

